CARDIFF ONCOLOGY INC(NASDAQ:CRDF) stock News

CRDF Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

a month ago - By: Cardiff Oncology, Inc.

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

2 months ago - By: Benzinga

A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts

2 months ago - By: Benzinga - Mentions: AMD CAT IT FOUR ...

AMD To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday

2 months ago - By: The Motley Fool

Cardiff Oncology (CRDF) Q2 Loss Down 19%

2 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

2 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

3 months ago - By: FN Media Group LLC - Mentions: ONCY ONC.CA MBIO VSTM ...

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

4 months ago - By: Yahoo Finance - Mentions: VZ

Cardiff Oncology to share CRDF-004 trial data on July 29

4 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

4 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

5 months ago - By: Zacks Investment Research

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

5 months ago - By: Zacks Investment Research - Mentions: IMTX

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

5 months ago - By: Zacks Investment Research - Mentions: ADCT

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

6 months ago - By: Zacks Investment Research

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?

6 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

6 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Cardiff Oncology, Inc.

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

7 months ago - By: Cardiff Oncology, Inc.

CARDIFF ONCOLOGY INC (CRDF) Stock News

CRDF Latest News, Press Relases and Analysis

Cardiff Oncology to Participate in Two Upcoming Investor Conferences

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

A Glimpse Into The Expert Outlook On Cardiff Oncology Through 4 Analysts

AMD To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)

Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

Cardiff Oncology to share CRDF-004 trial data on July 29

Cardiff Oncology Appoints Dr. Roger Sidhu as Chief Medical Officer and Announces Timing for the Next Update from the CRDF-004 Trial in First-Line RAS-mutated mCRC

Cardiff Oncology Announces Positive Data from Investigator-Initiated Trial of Onvansertib in Combination with Paclitaxel in Metastatic Triple-Negative Breast Cancer Presented at ASCO 2025

Cardiff Oncology (CRDF) Upgraded to Buy: Here's What You Should Know

Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates

ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?

Cardiff Oncology Announces a Second Patent for the Treatment of mCRC for Bev-Naïve Patients

Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer

Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update